Xphozah Dosage for Hyperphosphatemia in CKD on Dialysis
The recommended dosage of Xphozah (tenapanor) is 30 mg orally twice daily, taken just prior to the first and last meals of the day. 1
Dosing Algorithm
Starting Dose
- 30 mg twice daily (before morning and evening meals)
- This is both the starting and target maintenance dose 1
Timing Considerations
- Take just prior to meals (5-10 minutes before eating) to maximize 24-hour stool phosphorus excretion 1
- Do NOT take immediately before hemodialysis sessions - skip that dose and take before the next meal following dialysis to avoid diarrhea during treatment 1
- If a dose is missed, skip it entirely and resume at the next scheduled time 1
Dose Adjustments
- Monitor serum phosphorus and adjust dosage as needed for gastrointestinal tolerability 1
- The FDA label does not specify lower starting doses, but clinical trials evaluated 3 mg, 10 mg, and 30 mg doses with dose-dependent efficacy 2, 3
- If severe diarrhea develops, discontinue treatment 1
Clinical Context
Indication Specificity
Xphozah is indicated specifically as add-on therapy for adults with CKD on dialysis who have:
- Inadequate response to phosphate binders, OR
- Intolerance to any dose of phosphate binder therapy 1
This positions tenapanor as a second-line agent rather than monotherapy, though clinical trials demonstrated efficacy both as monotherapy and in combination with phosphate binders 1, 3.
Expected Efficacy
- Mean serum phosphate reductions of 1.0-1.2 mg/dL at the 30 mg twice-daily dose 3
- Dose-dependent reductions ranging from 0.47-1.98 mg/dL across different doses 2
- Real-world data from Japanese hemodialysis centers showed reduction from 6.5 to 5.4 mg/dL 4
Critical Safety Considerations
Diarrhea Management
Diarrhea is the primary adverse effect, occurring in 43-53% of patients 1:
- Most cases are mild-to-moderate and resolve over time
- Severe diarrhea occurs in 5% of patients
- Typically begins soon after initiation but can occur anytime
- Results from the drug's mechanism (NHE3 inhibition increases stool sodium and water) 3
- Discontinue if severe diarrhea develops 1
Contraindications
- Patients under 6 years of age (risk of serious dehydration) 1
- Known or suspected mechanical GI obstruction 1
Drug Interactions
- Enalapril exposure reduced by 64% when co-administered with tenapanor - consider this with ACE inhibitors 1
- No significant interactions with phosphate binders (sevelamer, calcium-based), digoxin, warfarin, or midazolam 1, 5
- Can be safely combined with phosphate binders without dose adjustment 5
Practical Implementation
Monitoring Parameters
- Serum phosphorus levels regularly
- Stool frequency and consistency
- Hydration status (particularly early in treatment)
- Serum sodium (modest reductions may occur) 6
Patient Education Priorities
Real-world survey data revealed that 58% of patients received information from non-clinical sources 7, highlighting the need for direct nephrologist counseling on:
- Proper timing relative to meals and dialysis
- Expected bowel changes (not necessarily pathologic diarrhea)
- When to report severe symptoms
- Importance of adherence (median 94% in real-world use) 7
Additional Benefits Beyond Phosphate Control
Emerging data suggest tenapanor may reduce:
- Interdialytic weight gain (3.1 to 2.9 kg, p=0.016) 4
- Blood pressure (both systolic and diastolic) 4
- Phosphate binder pill burden 4, 7
These effects correlate with the drug's mechanism of reducing intestinal sodium absorption alongside phosphate 6.